Matthew W. McClure's most recent trade in Aligos Therapeutics Inc was a trade of 72,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew McClure W. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 255,626 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew W. McClure | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 92,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | McClure Matthew W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 75,183 | 75,183 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 65,713 | 65,713 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew McClure W. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 23,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | McClure Matthew W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 16,428 | 16,428 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 46,000 | 46,000 | - | - | Stock Option (Right to Buy) |